Cargando…

Cost-effectiveness of pharmaceutical strategies to prevent respiratory syncytial virus disease in young children: a decision-support model for use in low-income and middle-income countries

BACKGROUND: Respiratory syncytial virus (RSV) is a leading cause of respiratory disease in young children. A number of mathematical models have been used to assess the cost-effectiveness of RSV prevention strategies, but these have not been designed for ease of use by multidisciplinary teams working...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mahmud, Sarwat, Baral, Ranju, Sanderson, Colin, Pecenka, Clint, Jit, Mark, Li, You, Clark, Andrew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088159/ https://www.ncbi.nlm.nih.gov/pubmed/37038127 http://dx.doi.org/10.1186/s12916-023-02827-5

Ejemplares similares

Impact and cost-effectiveness of potential interventions against infant respiratory syncytial virus (RSV) in 131 low-income and middle-income countries using a static cohort model
por: Baral, Ranju, et al.
Publicado: (2021)

Cost of childhood RSV management and cost-effectiveness of RSV interventions: a systematic review from a low- and middle-income country perspective
por: Wittenauer, Rachel, et al.
Publicado: (2023)

Cost of illness for childhood diarrhea in low- and middle-income countries: a systematic review of evidence and modelled estimates
por: Baral, Ranju, et al.
Publicado: (2020)

Evaluating the potential economic and health impact of rotavirus vaccination in 63 middle-income countries not eligible for Gavi funding: a modelling study
por: Debellut, Frédéric, et al.
Publicado: (2021)

Report of the WHO technical consultation on the evaluation of respiratory syncytial virus prevention cost effectiveness in low- and middle-income countries, April 7–8, 2022
por: Fitzpatrick, Meagan C., et al.
Publicado: (2023)

Inferring antenatal care visit timing in low- and middle-income countries: Methods to inform potential maternal vaccine coverage
por: Baral, Ranju, et al.
Publicado: (2020)

Mortality reduction benefits and intussusception risks of rotavirus vaccination in 135 low-income and middle-income countries: a modelling analysis of current and alternative schedules
por: Clark, Andrew, et al.
Publicado: (2019)

Re-evaluating the potential impact and cost-effectiveness of rotavirus vaccination in 73 Gavi countries: a modelling study
por: Debellut, Frédéric, et al.
Publicado: (2019)

Cost-effectiveness of measles and rubella elimination in low-income and middle-income countries
por: Levin, Ann, et al.
Publicado: (2023)

Impact and cost-effectiveness of strategies to prevent respiratory syncytial virus (RSV) disease in Vietnam: A modelling study
por: Do, Lien Anh Ha, et al.
Publicado: (2023)

Potential impact and cost-effectiveness of Shigella vaccination in 102 low-income and middle-income countries in children aged 5 years or younger: a modelling study
por: Anderson, John D, et al.
Publicado: (2023)

Forecasting Demand for the Typhoid Conjugate Vaccine in Low- and Middle-income Countries
por: Debellut, Frédéric, et al.
Publicado: (2019)

Forecasting demand for maternal influenza immunization in low- and lower-middle-income countries
por: Debellut, Frédéric, et al.
Publicado: (2018)

Potential impact and cost-effectiveness of future ETEC and Shigella vaccines in 79 low- and lower middle-income countries
por: Anderson, John D., et al.
Publicado: (2019)

The cost of entry: An analysis of pharmaceutical registration fees in low-, middle-, and high-income countries
por: Morgan, Steven G., et al.
Publicado: (2017)

Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models
por: Jit, Mark, et al.
Publicado: (2011)

The impact of maternal RSV vaccine to protect infants in Gavi-supported countries: Estimates from two models
por: Baral, Ranju, et al.
Publicado: (2020)

Assessing the value of human papillomavirus vaccination in Gavi-eligible low-income and middle-income countries
por: Ochalek, Jessica, et al.
Publicado: (2020)

Quality assurance systems of pharmaceutical distributors in low-income and middle-income countries: weaknesses and ways forward
por: Nebot Giralt, Ariadna, et al.
Publicado: (2020)

Lessons learned from the Advancing Maternal Immunization collaboration: identifying evidence gaps for informed respiratory syncytial virus maternal immunization decision-making
por: Groman, Devin, et al.
Publicado: (2019)

Respiratory syncytial virus seasonality and prevention strategy planning for passive immunisation of infants in low-income and middle-income countries: a modelling study
por: Li, You, et al.
Publicado: (2021)

The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study
por: Portnoy, Allison, et al.
Publicado: (2023)

The cost-effectiveness of hypertension management in low-income and middle-income countries: a review
por: Kostova, Deliana, et al.
Publicado: (2020)

Estimating the Economic Impact of Respiratory Syncytial Virus and Other Acute Respiratory Infections Among Infants Receiving Care at a Referral Hospital in Malawi
por: Baral, Ranju, et al.
Publicado: (2020)

Assessment of gestational age at antenatal care visits among Kenyan women to inform delivery of a maternal respiratory syncytial virus (RSV) vaccine in low- and middle-income countries
por: Nyiro, Joyce U., et al.
Publicado: (2023)

Estimating the global impact of rotavirus vaccines on child mortality
por: Clark, Andrew, et al.
Publicado: (2023)

Stark choices: exploring health sector costs of policy responses to COVID-19 in low-income and middle-income countries
por: Torres-Rueda, Sergio, et al.
Publicado: (2021)

The age profile of respiratory syncytial virus burden in preschool children of low- and middle-income countries: A semi-parametric, meta-regression approach
por: Antillón, Marina, et al.
Publicado: (2023)

The potential impact of novel tuberculosis vaccines on health equity and financial protection in low-income and middle-income countries
por: Portnoy, Allison, et al.
Publicado: (2023)

Cost-effectiveness of club-foot treatment in low-income and middle-income countries by the Ponseti method
por: Grimes, Caris E, et al.
Publicado: (2016)

Cost and cost-effectiveness of childhood cancer treatment in low-income and middle-income countries: a systematic review
por: Fung, Alastair, et al.
Publicado: (2019)

Pharmaceutical quality assurance of local private distributors: a secondary analysis in 13 low-income and middle-income countries
por: Van Assche, Kerlijn, et al.
Publicado: (2018)

Impact and cost-effectiveness of measles vaccination through microarray patches in 70 low-income and middle-income countries: mathematical modelling and early-stage economic evaluation
por: Fu, Han, et al.
Publicado: (2023)

Cost-effectiveness of maternal pertussis immunization: Implications of a dynamic transmission model for low- and middle-income countries
por: Kim, Sun-Young, et al.
Publicado: (2021)

Estimates of case-fatality ratios of measles in low-income and middle-income countries: a systematic review and modelling analysis
por: Portnoy, Allison, et al.
Publicado: (2019)

How much does it cost to scale up surgical systems in low-income and middle-income countries?
por: Jumbam, Desmond T., et al.
Publicado: (2019)

Management of neonatal jaundice in low-income and middle-income countries
por: Erdeve, Omer
Publicado: (2020)

Tackling antimicrobial resistance in low-income and middle-income countries
por: Pokharel, Sunil, et al.
Publicado: (2019)

Rotavirus vaccine protection in low-income and middle-income countries
por: Ramakrishnan, Girija, et al.
Publicado: (2019)

Improving childhood vaccination in low-income and middle-income countries
por: eBioMedicine
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3r2d12151l1beg07ohjbgmh7bh